Articles
肺癌诊断的进展：分子生物学对支气管镜诊断的贡献
Abstract
Keywords
References
McWilliams A, Lam B, Sutedja T. Early proximal lung cancer diagnosis and treatment. Eur Respir J, 2009(33):656-665.
Jagirdar J. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. Arch Pathol Lab Med,
(132):384-396.
Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol, 2010(41):20-25.
Ring BZ, Seitz RS, Beck RA, et al. A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Mod Pathol, 2009(22):1032-1043.
Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced nonsmall-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet, 2009(373):1525-1531.
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated nonsmall-cell lung cancer. N Engl J Med, 2005(353):123-132.
Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med, 2009(361):958-967.
Nomoto K, Tsuta K, Takano T, et al. Detection of EGFR mutations in archived cytologic specimens of nonsmall cell lung cancer using high-resolution melting analysis. Am J Clin Pathol, 2006(126):608-615.
Giaccone G. HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. Ann Oncol,
(16):538-548.
Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung ancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol, 2008(26):983-994.
Janne PA, Borras AM, Kuang Y, et al. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res, 2006(12):751-758.
Reed E. ERCC1 and clinical resistance to platinum-based therapy.Clin Cancer Res, 2005(11):6100-6102.
Simon G, Sharma A, Li X, et al. Feasibility and efficacy of molecular analysis- directed individualized therapy in advanced nonsmall-cell lung cancer. J Clin Oncol, 2007(25):2741-2746.
